3/4
10:25 am
canf
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
High
Report
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
3/4
07:25 am
canf
Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study [Yahoo! Finance]
High
Report
Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study [Yahoo! Finance]
3/4
07:00 am
canf
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
Medium
Report
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
2/17
07:00 am
canf
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
Low
Report
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
2/9
07:00 am
canf
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
Medium
Report
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
2/5
07:00 am
canf
Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
High
Report
Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
1/20
10:26 am
canf
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson [Yahoo! Finance]
Low
Report
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson [Yahoo! Finance]
1/20
07:00 am
canf
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
Medium
Report
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
12/26
07:00 am
canf
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
High
Report
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
12/23
04:46 pm
canf
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
High
Report
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
12/17
08:05 am
canf
Can-Fite BioPharma (NYSE:CANF) had its price target lowered by analysts at D. Boral Capital from $11.00 to $4.00. They now have a "buy" rating on the stock.
Low
Report
Can-Fite BioPharma (NYSE:CANF) had its price target lowered by analysts at D. Boral Capital from $11.00 to $4.00. They now have a "buy" rating on the stock.
12/16
09:19 am
canf
Can-Fite Provides Update on Clinical and Financial Status
Medium
Report
Can-Fite Provides Update on Clinical and Financial Status